{"id":17487,"date":"2025-07-29T17:05:16","date_gmt":"2025-07-29T15:05:16","guid":{"rendered":"https:\/\/www.ipcf.cnr.it\/?p=17487"},"modified":"2025-07-29T17:33:39","modified_gmt":"2025-07-29T15:33:39","slug":"braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical","status":"publish","type":"post","link":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/","title":{"rendered":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"17487\" class=\"elementor elementor-17487\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-538968a2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"538968a2\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-47995f7e\" data-id=\"47995f7e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-52d633be elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"52d633be\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;shape_divider_top&quot;:&quot;waves&quot;}\">\n\t\t\t\t\t<div class=\"elementor-shape elementor-shape-top\" aria-hidden=\"true\" data-negative=\"false\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewbox=\"0 0 1000 100\" preserveaspectratio=\"none\">\n\t<path class=\"elementor-shape-fill\" d=\"M421.9,6.5c22.6-2.5,51.5,0.4,75.5,5.3c23.6,4.9,70.9,23.5,100.5,35.7c75.8,32.2,133.7,44.5,192.6,49.7\tc23.6,2.1,48.7,3.5,103.4-2.5c54.7-6,106.2-25.6,106.2-25.6V0H0v30.3c0,0,72,32.6,158.4,30.5c39.2-0.7,92.8-6.7,134-22.4\tc21.2-8.1,52.2-18.2,79.7-24.2C399.3,7.9,411.6,7.5,421.9,6.5z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-26c34cc4\" data-id=\"26c34cc4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-60d33ce3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"60d33ce3\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f51c9ff\" data-id=\"f51c9ff\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3d14dcc7 elementor-widget elementor-widget-image\" data-id=\"3d14dcc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"640\" height=\"390\" src=\"http:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA_PNRR_BRAVEHEART.png\" class=\"attachment-large size-large wp-image-17488\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-34d0c7e1\" data-id=\"34d0c7e1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2a930262 elementor-widget elementor-widget-text-editor\" data-id=\"2a930262\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Durata:<\/strong> 25 Novembre 2024- 24 Novembre 2026 (2 anni)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61e80dcd elementor-widget elementor-widget-text-editor\" data-id=\"61e80dcd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b>Ente finanziatore:<\/b> Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU &#8211; Project PNRR-POC-2023-12378186<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-53e61dfd elementor-widget elementor-widget-text-editor\" data-id=\"53e61dfd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Principal Investigator:<\/strong> Michele Pilato (ISMETT-\u00a0Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione IRCCS)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2dc09659 elementor-widget elementor-widget-text-editor\" data-id=\"2dc09659\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Referente IPCF:<\/strong> <a href=\"https:\/\/www.ipcf.cnr.it\/it\/team\/caterina-cristallini\/\" target=\"_blank\" rel=\"noopener\">C. Cristallini<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6ce83318 elementor-widget elementor-widget-text-editor\" data-id=\"6ce83318\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Unit\u00e0 di ricerca coinvolte (referente):<\/strong> Universit\u00e0 di Torino (Mauro Rinaldi); AOU San Giovanni di Dio e Ruggi d\u2019Aragona (Carmine Vecchione) <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-2804786f elementor-widget elementor-widget-spacer\" data-id=\"2804786f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-12b88410 elementor-widget elementor-widget-text-editor\" data-id=\"12b88410\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b>Settori ERC:<\/b>LS7_4 Regenerative medicine; PE5_7 Biomaterials synthesis; LS7_3 Nanomedicine<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22367019 elementor-widget elementor-widget-text-editor\" data-id=\"22367019\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b>Parole chiave: <\/b>Cardiac repair; Regeneration; Drug-eluting; Acellular patch<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7d221390 elementor-widget elementor-widget-text-editor\" data-id=\"7d221390\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Il progetto rappresenta un\u2019iniziativa integrata clinico-traslazionale per il trasferimento tecnologico di cerotti cardiaci innovativi, microstrutturati, elettroconduttivi e a rilascio di farmaco, concepiti come soluzioni terapeutiche rivoluzionarie per prevenire l\u2019insufficienza cardiaca. Un team formato da unit\u00e0 cliniche, accademiche e di ricerca con competenze complementari (medicina, cardiochirurgia, biologia delle cellule staminali e bioingegneria) condurr\u00e0 il progetto. L\u2019IPCF sar\u00e0 responsabile della produzione e della caratterizzazione chimico-fisica, meccanica e funzionale dei cerotti cardiaci sviluppati.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51358b13 elementor-widget elementor-widget-text-editor\" data-id=\"51358b13\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Altro personale IPCF coinvolto nelle attivit\u00e0 di ricerca:<\/strong> <a href=\"https:\/\/www.ipcf.cnr.it\/it\/team\/federica-aiello\/\" target=\"_blank\" rel=\"noopener\">F. Aiello<\/a>, <a href=\"https:\/\/www.ipcf.cnr.it\/it\/team\/cheherazade-trouki\/\" target=\"_blank\" rel=\"noopener\">C. Trouki<\/a>, <a href=\"https:\/\/www.ipcf.cnr.it\/it\/team\/dawid-rossino\/\" target=\"_blank\" rel=\"noopener\">D. Rossino<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Duration: From 25 Nov 2024 &#8211; 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU &#8211; Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT-\u00a0Istituto Mediterraneo per i Trapianti e Terapie [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":17496,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[101,112,107,97],"tags":[],"post_formats":[],"class_list":["post-17487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-active-projects","category-national","category-pnrr","category-projects"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.8 - aioseo.com -->\n\t<meta name=\"description\" content=\"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"federica\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"it_IT\" \/>\n\t\t<meta property=\"og:site_name\" content=\"IPCF -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF\" \/>\n\t\t<meta property=\"og:description\" content=\"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-07-29T15:05:16+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-07-29T15:33:39+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie\" \/>\n\t\t<meta name=\"twitter:image\" content=\"http:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#blogposting\",\"name\":\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF\",\"headline\":\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation\",\"author\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/author\\\/federica\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/GA-quadrato.png\",\"width\":1280,\"height\":720},\"datePublished\":\"2025-07-29T17:05:16+02:00\",\"dateModified\":\"2025-07-29T17:33:39+02:00\",\"inLanguage\":\"it-IT\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#webpage\"},\"articleSection\":\"Active projects, National, PNRR, Projects\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/#listItem\",\"name\":\"Projects\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/#listItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/active-projects\\\/#listItem\",\"name\":\"Active projects\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/active-projects\\\/#listItem\",\"position\":3,\"name\":\"Active projects\",\"item\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/active-projects\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#listItem\",\"name\":\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/#listItem\",\"name\":\"Projects\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#listItem\",\"position\":4,\"name\":\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/category\\\/projects\\\/active-projects\\\/#listItem\",\"name\":\"Active projects\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/#organization\",\"name\":\"ipcf\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/ipcflogo_0924_nobkg_rid.png\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#organizationLogo\",\"width\":500,\"height\":145},\"image\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/author\\\/federica\\\/#author\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/author\\\/federica\\\/\",\"name\":\"federica\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f203aa0b3691a7589936618baf6fc9972cff832c3ae59aab9f0591c7a6c6300?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"federica\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#webpage\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/\",\"name\":\"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF\",\"description\":\"Duration: From 25 Nov 2024 \\u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \\u201cValorizzazione e potenziamento della ricerca biomedica del SSN\\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\\u2019Unione Europea, NextGenerationEU \\u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie\",\"inLanguage\":\"it-IT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/author\\\/federica\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/author\\\/federica\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/GA-quadrato.png\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#mainImage\",\"width\":1280,\"height\":720},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\\\/#mainImage\"},\"datePublished\":\"2025-07-29T17:05:16+02:00\",\"dateModified\":\"2025-07-29T17:33:39+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/\",\"name\":\"ipcf\",\"inLanguage\":\"it-IT\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ipcf.cnr.it\\\/it\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF","description":"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie","canonical_url":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#blogposting","name":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF","headline":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation","author":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/author\/federica\/#author"},"publisher":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png","width":1280,"height":720},"datePublished":"2025-07-29T17:05:16+02:00","dateModified":"2025-07-29T17:33:39+02:00","inLanguage":"it-IT","mainEntityOfPage":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#webpage"},"isPartOf":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#webpage"},"articleSection":"Active projects, National, PNRR, Projects"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it#listItem","position":1,"name":"Home","item":"https:\/\/www.ipcf.cnr.it\/it","nextItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/#listItem","name":"Projects"}},{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/#listItem","position":2,"name":"Projects","item":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/#listItem","name":"Active projects"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/#listItem","position":3,"name":"Active projects","item":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#listItem","name":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/#listItem","name":"Projects"}},{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#listItem","position":4,"name":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation","previousItem":{"@type":"ListItem","@id":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/#listItem","name":"Active projects"}}]},{"@type":"Organization","@id":"https:\/\/www.ipcf.cnr.it\/it\/#organization","name":"ipcf","url":"https:\/\/www.ipcf.cnr.it\/it\/","logo":{"@type":"ImageObject","url":"https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2024\/09\/ipcflogo_0924_nobkg_rid.png","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#organizationLogo","width":500,"height":145},"image":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/www.ipcf.cnr.it\/it\/author\/federica\/#author","url":"https:\/\/www.ipcf.cnr.it\/it\/author\/federica\/","name":"federica","image":{"@type":"ImageObject","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/6f203aa0b3691a7589936618baf6fc9972cff832c3ae59aab9f0591c7a6c6300?s=96&d=mm&r=g","width":96,"height":96,"caption":"federica"}},{"@type":"WebPage","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#webpage","url":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/","name":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF","description":"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie","inLanguage":"it-IT","isPartOf":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/#website"},"breadcrumb":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#breadcrumblist"},"author":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/author\/federica\/#author"},"creator":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/author\/federica\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png","@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#mainImage","width":1280,"height":720},"primaryImageOfPage":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/#mainImage"},"datePublished":"2025-07-29T17:05:16+02:00","dateModified":"2025-07-29T17:33:39+02:00"},{"@type":"WebSite","@id":"https:\/\/www.ipcf.cnr.it\/it\/#website","url":"https:\/\/www.ipcf.cnr.it\/it\/","name":"ipcf","inLanguage":"it-IT","publisher":{"@id":"https:\/\/www.ipcf.cnr.it\/it\/#organization"}}]},"og:locale":"it_IT","og:site_name":"IPCF -","og:type":"article","og:title":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF","og:description":"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie","og:url":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/","og:image":"https:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png","og:image:secure_url":"https:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png","article:published_time":"2025-07-29T15:05:16+00:00","article:modified_time":"2025-07-29T15:33:39+00:00","twitter:card":"summary_large_image","twitter:title":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation - IPCF","twitter:description":"Duration: From 25 Nov 2024 \u2013 24 Nov 2026 (2 years) Funding Institution: Investimento 2.1 \u201cValorizzazione e potenziamento della ricerca biomedica del SSN\u201d, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall\u2019Unione Europea, NextGenerationEU \u2013 Project PNRR-POC-2023-12378186 Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie","twitter:image":"http:\/\/150.145.64.139\/wp-content\/uploads\/2023\/01\/cropped-logo-ipcf-e1674465398734.png"},"aioseo_meta_data":{"post_id":"17487","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2025-07-29 15:05:16","updated":"2025-07-29 15:33:39","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.ipcf.cnr.it\/it\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/\" title=\"Projects\">Projects<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/\" title=\"Active projects\">Active projects<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tBRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.ipcf.cnr.it\/it"},{"label":"Projects","link":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/"},{"label":"Active projects","link":"https:\/\/www.ipcf.cnr.it\/it\/category\/projects\/active-projects\/"},{"label":"BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation","link":"https:\/\/www.ipcf.cnr.it\/it\/braveheart-a-new-versatile-technological-bioartificial-drug-eluting-cardiac-patch-to-prevent-heart-failure-from-clinically-oriented-de-risking-activity-to-the-industrial-prototyping-and-preclinical\/"}],"guten_post_layout_featured_media_urls":{"full":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1280,720,false],"thumbnail":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",150,84,false],"medium":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",300,169,false],"medium_large":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",640,360,false],"large":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",640,360,false],"1536x1536":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1280,720,false],"2048x2048":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1280,720,false],"trp-custom-language-flag":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",18,10,false],"wpca-thumb":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",220,124,false],"guten_post_layout_landscape_large":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1200,675,false],"guten_post_layout_portrait_large":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1200,675,false],"guten_post_layout_square_large":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",1200,675,false],"guten_post_layout_landscape":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",600,338,false],"guten_post_layout_portrait":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",600,338,false],"guten_post_layout_square":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",600,338,false],"academix-single-team-thumb":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",360,203,false],"academix-team-thumbnail":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",263,148,false],"academix-event-thumbnail":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",555,312,false],"academix-event-gallery-thumb":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",227,128,false],"academix-blog-thumb":["https:\/\/www.ipcf.cnr.it\/wp-content\/uploads\/2025\/07\/GA-quadrato.png",100,56,false]},"_links":{"self":[{"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/posts\/17487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/comments?post=17487"}],"version-history":[{"count":4,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/posts\/17487\/revisions"}],"predecessor-version":[{"id":17493,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/posts\/17487\/revisions\/17493"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/media\/17496"}],"wp:attachment":[{"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/media?parent=17487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/categories?post=17487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/tags?post=17487"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/www.ipcf.cnr.it\/it\/wp-json\/wp\/v2\/post_formats?post=17487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}